<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Lupus-Nephritis on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/lupus-nephritis/</link><description>Recent content in Lupus-Nephritis on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Sun, 21 Jun 2026 06:00:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/lupus-nephritis/index.xml" rel="self" type="application/rss+xml"/><item><title>Pathogenesis-Directed Lupus Therapeutics</title><link>https://rheumatologydigest.org/posts/pathogenesis-directed-lupus-therapeutics/</link><pubDate>Sun, 21 Jun 2026 06:00:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/pathogenesis-directed-lupus-therapeutics/</guid><description>A 2026 review of pathogenesis-directed SLE therapeutics anchored to the 2025 ACR SLE and 2024 ACR lupus nephritis guidelines — the FDA-approved and off-label drugs by mechanism, indication and monitoring, plus the metabolic/mitochondrial, IL-1, cardiometabolic and non-pharmacological strategies, mapped by organ manifestation.</description></item></channel></rss>